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Abstract
Hematopoietic progenitor CD133
+/c-kit
+ cells have been shown to be involved in myocardial healing following myocardial
infarction (MI). Previously we demonstrated that angiopoietin-1(Ang-1) is beneficial in the repair of diabetic infarcted hearts.
We now investigate whether Ang-1 affects CD133
+/c-kit
+ cell recruitment to the infarcted myocardium thereby mediating
cardiac repair in type II (db/db) diabetic mice. db/db mice were administered either adenovirus Ang-1 (Ad-Ang-1) or Ad-b-
gal systemically immediately after ligation of the left anterior descending coronary artery (LAD). Overexpression of Ang-1
resulted in a significant increase in CXCR-4/SDF-1a expression and promoted CD133
+/c-kit
+, CD133
+/CXCR-4
+ and CD133
+/
SDF-1a
+ cell recruitment into ischemic hearts. Overexpression of Ang-1 led to significant increases in number of CD31
+ and
smooth muscle-like cells and VEGF expression in bone marrow (BM). This was accompanied by significant decreases in
cardiac apoptosis and fibrosis and an increase in myocardial capillary density. Ang-1 also upregulated Jagged-1, Notch3 and
apelin expression followed by increases in arteriole formation in the infarcted myocardium. Furthermore, overexpression of
Ang-1 resulted in a significant improvement of cardiac functional recovery after 14 days of ischemia. Our data strongly
suggest that Ang-1 attenuates cardiac apoptosis and promotes cardiac repair by a mechanism involving in promoting
CD133
+/c-kit
+ cells and angiogenesis in diabetic db/db mouse infarcted hearts.
Citation: Zeng H, Li L, Chen J-X (2012) Overexpression of Angiopoietin-1 Increases CD133+/c-kit+ Cells and Reduces Myocardial Apoptosis in db/db Mouse
Infarcted Hearts. PLoS ONE 7(4): e35905. doi:10.1371/journal.pone.0035905
Editor: Ferenc Gallyas, University of Pecs Medical School, Hungary
Received November 7, 2011; Accepted March 23, 2012; Published April 2 , 2012
Copyright:  2012 Zeng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant from the United States National Institutes of Health, HL102042. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: JChen3@umc.edu
Introduction
Ang-1 is an oligomeric-secreted glycoprotein, which binds to
Tie-2 and induces Tie-2 phosphorylation. Ang-1 is recognized as
a survival factor for endothelial cells (EC). Treatment with Ang-1
prevents EC apoptosis via activation of the PI3K/Akt path-
way.[1,2] Ang-1 has also been shown to prevent diabetic
retinopathy by attenuating retinal permeability in the streptozo-
tocin (STZ)-induced rat diabetic model.[3] Our previous studies
revealed that overexpression of Ang-1 in diabetic db/db mouse
heart restores Tie-2 expression and significantly increases
myocardial capillary formation; this is accompanied by a dramatic
decrease in myocardial hypertrophy and cardiac fibrosis.[4] These
data implicate Ang-1 as a potential therapeutic target in the
treatment of diabetic cardiovascular complications.
Endothelial progenitor cells (EPCs) home to sites of ischemia
and contribute to neovascularization in ischemic tissue.[5]
Experimental and clinical studies demonstrate that treatment of
acute myocardial infarction with EPCs results in a reduction in
infarct size.[6,7] Vascular progenitor cells have been shown to
differentiate into cardiomyocytes and vascular smooth muscle cells
(VSMC), which may contribute to cardiac and/or vascular
regeneration following myocardial infarction [8,9]. Intriguingly,
the differentiation of EPCs is impaired in both diabetic patients
with coronary artery disease and in diabetic mouse models
[10,11]. Previously we demonstrate that the level of EPCs is
significantly decreased in STZ-induced diabetic mouse compared
to non-diabetic mice [12]. Our previous studies also reveal that
disruption of BM-EPC differentiation and impairment of angio-
genesis after myocardial ischemia are associated with larger
myocardial infarct size in the diabetic STZ mice [12]. These
studies suggest that impaired vascular progenitor cell recruitment
and failure of BM differentiation to EPCs after MI may contribute
to insufficient angiogenesis and exacerbation of MI in diabetes.
Thus, an agent that promotes vascular progenitor cell recruitment
and angiogenesis will be beneficial for ischemic injury repair and
cardiac remodeling after MI in diabetic hearts. This notion is
supported by our previous work demonstrating that overexpres-
sion of Ang-1 significantly increased myocardial angiogenesis and
reduced myocardial infarction size in the STZ diabetic mouse
model [12]. However, the underlying molecular mechanism by
which Ang-1 attenuates myocardial ischemic injury in the diabetic
heart following MI remains poorly understood.
Ang-1 has been shown to have a critical role in the maintenance
of hematopoietic stem cell in the bone marrow through its binding
to the Tie-2 receptor.[13]The hematopoietic stem cell cytokine
SDF-1a and it receptor CXCR-4 have been identified as the
central signaling axis that regulates recruitment of hematopoietic
stem cells into the injured area of myocardial ischemia and in
improvement of cardiac function after MI [14]. Using diabetic db/
db mice subjected to myocardial ischemia, the present study
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7investigates whether overexpression of Ang-1 promotes recruit-
ment of hematopoietic progenitor cells into ischemic sites and
whether this leads to attenuation of myocardial ischemic injury
through SDF-1a/CXCR-4 signaling. Our data suggest that Ang-
1/Tie-2 plays a crucial role in regulation of hematopoietic
progenitor cell recruitment and cardiac repair in the diabetic
infarcted heart.
Methods
Ethics Statement
All procedures conformed to the Institute for Laboratory
Animal Research Guide for the Care and Use of Laboratory
Animals and were approved by the University of Mississippi
Medical Center Institutional Animal Care and Use Committee
(Protocol ID: #1280).
Diabetic mouse myocardial ischemia model
db/db mice (12–14 weeks of age) were purchased from Jackson
Laboratory (Bar Harbor, Maine). Experimental mice were
anesthetized with ketamine (100 mg/kg) plus xylazine (15 mg/
kg), intubated and artificially ventilated with room air. Adequate
anesthesia was monitored by toe pinch. A left thoracotomy was
performed and myocardial ischemia was achieved by ligation of
the left anterior descending coronary artery (LAD) [12,15]. Sham
controls underwent the surgery without LAD ligation. Experi-
mental mice were divided into three groups: (1) sham control
(n=12 mice); (2) Ad-b-gal + ischemia 24 hours (n=22 mice) and
14 days (n=13 mice) and (3) Ad-Ang-1 + ischemia 24 hours
(n=16 mice) and 14 days (n=19 mice). Experimental mice were
sacrificed under anesthesia with isoflurane at 24 hours and
14 days after LAD ligation for the analyses described below.
Systemic delivery of Ang-1 to experimental mice
After surgery, db/db mice received an intravenous tail vein
injection of either Ad-Ang-1 (1610
9 PFU) or Ad-b-gal (1610
9
PFU) [4,12].
Western analysis of Ang-1, SDF-1a, VEGF, apelin, APLNR
(APJ), Jagged 1 and Notch3 expression
After 24 hours of myocardial ischemia, the hearts and BM were
harvested and homogenized in lysis buffer. The membranes were
immunoblotted with SDF-1a, VEGF, apelin, APNLR, Jagged1
and Notch3 (1:1000, Santa Cruz, CA) or Ang-1 (1:1000, Sigma,
MO) antibodies. The membranes were washed and incubated
with a secondary antibody coupled to horseradish peroxidase and
densitometric analysis was carried out using image acquisition and
analysis software (TINA 2.0).
Myocardial Ang-1, Tie-2, CD133, CD45, C-kit, CXCR-4,
SDF-1a, SMA and Notch3 expression
Heart tissue sections (8 mm thick) were incubated with Ang-1,
CD133, Tie-2 and Notch3, CXCR-4, CD45, c-kit and SDF-1a
(1:200 Santa Cruz, CA) antibodies overnight. Ang-1, CD133, Tie-
2 and Notch3 were visualized using FITC labeled goat anti-mouse
IgG antibodies; CXCR-4, CD45 and SDF-1a were visualized with
Fluorolink
TM Cy
TM3 labeled goat anti-mouse IgG antibodies
(1:200). Cy3-conjugated anti-a smooth muscle actin (SMA, 1:100;
Sigma, MO) was used to identify smooth muscle cells. Myocardial
CD133, CD45 and CXCR-4 expression was assessed by counting
the number of positive cells per square millimeter (mm
2) of tissue.
Co-localization of CD133 with either CXCR-4 or SDF-1a,o r
Ang-1 with SMA was visualized with a fluorescence microscope
(Nikon TE 2000, Japan). Sections were counterstained with DAPI.
Bone marrow (BM) cell differentiation into CD31
+ and
SMA
+ cells
At 24 hours of myocardial ischemia, BM cells were obtained by
flushing the tibias and femurs with 10% FBS EGM. Immediately
after isolation, 10
5 bone marrow–derived mononuclear cells were
plated on 6-well culture plates coated with fibronectin (50 mg/ml,
Sigma). After 4 days of culture, the nonadherent cells were
removed and the adherent cells were incubated with -FITC-
labeled CD31 antibody (1:100, BD Biosciences) and -Cy3-
conjugated anti-a smooth muscle actin (SMA, 1:100; Sigma,
MO). Positively-stained cells were counted per 10
5 BM cells.
Analysis of myocardial capillary density
After 14 days of myocardial ischemia, the hearts were harvested
and immediately flash frozen. Five mm sections were incubated
with Isolectin B4 (1:200, IB4, Molecular Probe, Invitrogen) to
identify capillaries. The number of capillaries was counted and
expressed as capillary density per square millimeter (mm
2) [12,16].
Analysis of VSMC and arteriole formation
To assess VSMC in the border zone of the ischemic area after
24 hours of MI, VSMC were stained with Cy3-conjugated anti-
a smooth muscle actin (SMA, 1:100; Sigma, MO). Arterioles (Ang-
1
+/SMA
+) was examined at 14 days of MI.
Myocardial cell/endothelial apoptosis
Heart tissue sections underwent transferase deoxyuridine nick
end labeling (TUNEL) following the manufacturer’s instructions
(Promega, WI). Sections were counterstained with DAPI.
Apoptosis was indexed by counting TUNEL positive cells per
square millimeter (mm
2). To determine endothelial or SMC
apoptosis, sections of myocardium were incubated with TUNEL
and vWF (1:200, Santa Cruz, CA) or Cy3-conjugated anti-
a smooth muscle actin (SMA, 1:100; Sigma, MO) overnight,
followed by incubation with Fluorolink
TM Cy
TM3 for vWF. Co-
localization of TUNEL with vWF or SMA was visualized with
a fluorescence microscope (Nikon TE 2000, Japan). Sections were
counterstained with DAPI. Endothelial cell/SMC apoptosis was
indexed by counting TUNEL/vWF or TUNEL/SMA positive
cells per square millimeter (mm
2).
Assessment of cardiac function
Briefly, experimental mice were anesthetized with ketamine
(100 mg/kg) plus xylazine (15 mg/kg), intubated and artificially
ventilated with room air. A 1.4-Fr pressure–conductance catheter
(SPR-839, Millar Instrument, Houston, TX) was insert into left
ventricle (LV) to record baseline hemodynamics of hearts. Data
were digitized with a sampling rate of 1000 Hz. All data were
analyzed with LabChart software package from AD instruments.
Myocardial fibrosis and heart weight to body weight
ratio (HW/BW)
To determine cardiac fibrosis formation, 8 mm sections from
hearts after 14 days of myocardial ischemia were stained with
Masson’s trichrome (MT, Sigma, MO). Myocardial fibrosis was
quantified by measuring the MT staining area (blue) in the
infarcted area using NIH Image analysis software [4]. Cardiac
hypertrophy was assessed by measuring heart-to-body weight ratio
at 14 days post-myocardial ischemia. Each heart weight was
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representative of cardiac hypertrophy.
Statistical analysis
All results are expressed as mean 6 SD. Statistical analysis was
performed using one-way ANOVA followed by the multiple-
comparison test (Student–Newman–Keuls or Dunn’s test). A p
value ,0.05 denoted significance.
Results
Overexpression of Ang-1 in diabetic db/db mouse hearts
and bone marrow
Systemic delivery of Ad-Ang-1 led to dramatic induction of
Ang-1 expression in db/db mouse hearts and bone marrow after
24 hours of myocardial ischemia (Figure 1A). Fluorescent
immunohistochemical analysis confirmed the overexpression of
Ang-1 in the Ad-Ang-1 treated db/db mouse hearts and bone
marrow, but not in the Ad-b-gal treated db/db mouse hearts and
bone marrow (Figure 1B). We also examined the location of
Ang-1 expression in Ad-Ang-1–treated db/db mouse hearts. Our
merged images revealed that Ang-1 localized with Isolectin B4
(IB4) on ECs and SMA on vessel SMCs (Figure 1C). To examine
transfection efficiency of Ad-Ang-1 in vivo, experimental mice were
systemic administrated with Ad-Ang-1 at dosage of 10
7–10
9 pfu
for 24 hours. Western blot analysis showed that Ang-1 protein
expression was gradual increased in a dose dependent fashion both
in the heart and bone marrow (Figure 1D).
Overexpression of Ang-1 promotes hematopoietic stem
cell recruitment via SDF-1a/CXCR-4 signaling in the
ischemic hearts of db/db mouse
Next, we investigated whether overexpression of Ang-1 affects
recruitment of hematopoietic progenitor cells into infarcted db/db
mouse hearts. CD133 and c-kit cells were examined in the
ischemic hearts at 24 hour and 14 days. No CD133
+ cells were
observed in the sham control db/db mouse hearts without
ischemia. As shown in Figure 2A and 2B, CD133
+ cells were
recruited into diabetic mouse infarcted hearts after 24 hours
ischemia as compared to Ad-b-gal diabetic mouse infarcted hearts.
Overexpression of Ang-1 led to a significant increase in CD133
+
cells in diabetic infarcted hearts in comparison with Ad-b-gal
treated db/db mice. Furthermore, no c-kit
+ cells were detected in
the sham control, db/db+ ischemia and db/db + ischemia+Ad-
Ang-1 at 24 hours. Intriguingly, c-kit
+ cells were detected in the
Ad-Ang-1 diabetic mouse infarcted hearts at day 14 of ischemia,
but not in Ad-b-gal diabetic mouse. The recruited c-kit
+ cells were
co-localized with CD133
+ cells in db/db mouse infarcted hearts
treated with Ad-Ang-1 (Figure 2C).
CD45
+ positive cells were also dramatically increased in diabetic
infarcted hearts treated with Ad-Ang-1 at 24 hours after MI as
compared to Ad-b-gal diabetic mouse infarcted hearts. Co-
Figure 1. Expression and localization of Ang-1 in the diabetic db/db mouse hearts and bone marrow. (A) Western blot analysis
demonstrating that systemic administration of Ad-Ang-1 (1610
9 PFU) resulted in overexpression of Ang-1 in the db/db mouse hearts and bone
marrow at day 1 compared to mice receiving Ad-b-gal. (B) Ang-1 was stained with an Ang-1 antibody-labeled with FITC (green, 40X) and nuclei were
stained with DAPI (blue, 40X). Merged images show Ang-1 expression in Ad-Ang-1 treated db/db mouse hearts and bone marrow (right panel), but
not in Ad-b-gal treated db/db mouse hearts and bone marrow (left panel). (C) Ang-1 protein was localized at smooth muscle cell (SMC) and
endothelial cell (EC) in heart tissue. Ang-1 expression was imunostained with Texas Red (red). Endothelial cells were stained with LB4 (green). Merged
image revealed that Ang-1 was localized to EC (left panel). Ang-1 was stained with Ang-1 linked to FITC (green). SMCs were stained with SMA (Red)
and nuclei were stained with DAPI counterstaining (blue). Merged image showed that Ang-1was localized to SMC (right panel). (D) Western blot
analysis demonstrating that systemic administration of Ad-Ang-1 (1610
7 –1610
9 PFU) resulted in overexpression of Ang-1 in the mouse hearts and
bone marrow in a dose-dependent manner.
doi:10.1371/journal.pone.0035905.g001
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+ cells
co-localized with Tie-2
+ in diabetic infarcted hearts treated with
Ad-Ang-1 (Figure 2D and E).
To examine the roles of SDF-1a/CXCR-4 in Ang-1-induced
CD133
+ cell recruitment into db/db mouse hearts, we examined
the number of CXCR-4
+ cells and SDF-1a/CXCR-4 protein
expression in the border zone of infarcted myocardium after
24 hours of MI. As shown in Figure 3A and B, overexpression of
Ang-1 in db/db mice led to a significant increase in the number of
CXCR-4
+ cells in the border zone of infarcted hearts in
comparison with Ad-b-gal treated db/db mice. No CXCR-4
+
cells were found in the sham control db/db mouse hearts. Western
blot analysis revealed that overexpression of Ang-1 resulted in
significant increases in CXCR-4 and SDF-1a expression in
diabetic infarcted hearts as compared to Ad-b-gal diabetic mouse
infarcted hearts (Figure 3 C and D). Co-localization studies
further revealed that the increased CD133
+ co-localized with
CXCR-4
+ and SDF-1a
+ cells in diabetic infarcted hearts treated
with Ad-Ang-1 (Figure 3E).
Overexpression of Ang-1 attenuates myocardial
apoptosis and reduces cardiac fibrosis in diabetic db/db
mouse hearts
We further sought to determine whether increased recruitment
of CD133
+/c-kit
+ cells into the ischemic area by Ang-1 would
minimize myocardial apoptosis. TUNEL staining and quantitative
analysis revealed a significant increase in TUNEL-positive cells in
the infarcted area of db/db mice after 24 hours and 14 days of MI
compared to sham control db/db mice. db/db mice treated with
Ad-Ang-1 had significantly fewer TUNEL-positive cells in the
infarct area compared to db/db mice that received Ad-b-gal
Figure 2. Ang-1 promotes hematopoietic stem cell recruitment into the ischemic hearts of db/db mouse. A. Recruitment of CD133
+ in
db/db mouse hearts subjected to myocardial ischemia at 24 hours. The hematopoietic stem cells were stained with a CD133 antibody (green, 40X).
The nuclei were stained by DAPI (blue, 40X). B: Quantitative analysis of CD133
+ cells demonstrating that the number of CD133
+ cells was significantly
increased in the Ad-Ang-1 treated db/db mice (n=6) compared to that of Ad-b-gal-treated db/db mice (n=9). CD133
+ cells are expressed as the total
number per square mm. Sham control (n=3). All data represent mean 6 SD; *p,0.05. ND= not detected. C. Co-localization of CD133 with c-kit in
db/db mouse infarcted hearts at 14 days of MI. CD133
+ cells (green); c-kit
+ cells (red) and nuclei were stained by DAPI (blue, 40X). C-kit
+ cells were
recruited into diabetic db/db mouse infarcted hearts in the Ad-Ang-1 treated db/db mice. Merged images further show that CD133
+ cells were co-
localized with c-kit
+ cells. No c-kit
+ cells were seen in the Ad-b-gal-treated db/db mice. No specific staining was observed in the sham control group.
n=3 mice each group. D. Recruitment of hematopoietic CD45
+ cells in db/db mouse hearts subjected to myocardial ischemia at 24 hours. The
hematopoietic cells were stained with a CD45 antibody (red, 40X). The endothelial cells were stained with a Tie-2 antibody (green). The nuclei were
stained by DAPI (blue, 40X). No specific staining was observed in the sham control group. E: Quantitative analysis of CD45
+ cells demonstrating that
the number of CD45
+ cells was significantly increased in the Ad-Ang-1 treated db/db mice (n=6) compared to that of Ad-b-gal-treated db/db mice
(n=9). CD45
+ cells are expressed as the total number per square mm. Sham control (n=3). All data represent mean 6 SD; *p,0.05. ND= not
detected.
doi:10.1371/journal.pone.0035905.g002
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revealed that treatment of db/db mice with Ad-Ang-1 significantly
attenuated the number of TUNEL/vWF-positive cells in the
infarct area compared to db/db mice that received Ad-b-gal
(Figure 4A and C). Similarly, treatment of db/db mice with Ad-
Ang-1 for 24 hours significantly reduced myocardial apoptosis in
the remote area of ischemia compared to db/db mice that
received Ad-b-gal (Figure 4D). However, treatment with Ad-
Ang-1 has little effect on the number of TUNEL/SMA positive
cells (Figure 4E). Compared to db/db mice treated with Ad-b-
gal, mice treated with Ad-Ang-1 showed a significant decrease in
the area of myocardial fibrosis at 14 days after MI (Figure 4F).
At 14 days, treatment with Ad-Ang-1 led to a significant decrease
in the HW/BW ratio in db/db mice subjected to MI as compared
with db/db mice treated with Ad-b-gal (Figure 4G).
Overexpression of Ang-1 increases the number of BM-
CD31
+ cells and myocardial capillary density in db/db
mouse hearts
New evidence indicates that BM-CD31+ cells have angiogenic
properties and implantation of BM-CD31
+ cells into ischemic
hind-limb promotes recovery of tissue from ischemic injury [17].
Therefore, we examined the number of BM-CD31
+ cells after
Figure 3. Ang-1 upregulates SDF-1a and CXCR-4 expression in the ischemic hearts of db/db mouse. A: Expression of CXCR-4 in db/db
mouse hearts subjected to myocardial ischemia at 24 hours. CXCR-4 positive cell (red) and nuclei were stained by DAPI (blue). B: Quantitative analysis
showing that the number of CXCR-4
+ cells was significantly increased in the Ad-Ang-1 treated db/db mice (n=6) compared to that of Ad-b-gal-
treated db/db mice (n=9). CXCR-4
+ cells are expressed as the total number per square mm. Sham control (n=3). All data represent mean 6 SD;
*p,0.05. ND= not detected. C: Western blot and densitometric analysis of myocardial CXCR-4 expression showing that overexpression of Ang-1
significantly increased CXCR-4 expression in db/db mice compared to that of Ad-b-gal-treated db/db mice. All data represent mean 6 SD (n=4 mice);
*p,0.05. D. Western blot and densitometric analysis of myocardial SDF-1a expression. Overexpression of Ang-1 significantly increased SDF-1a
expression in db/db mice compared to that of Ad-b-gal-treated db/db mice. All data represent mean 6 SD (n=4 mice); *p,0.05. E. Co-localization of
CD133 with CXCR-4 and CD133 with SDF-1a in db/db mouse infarcted hearts. CD133
+ cells (green); CXCR-4
+ or SDF-1a
+ cells (red) and nuclei were
stained by DAPI (blue, 40X). Merged images show that CD133
+ cells co-localized with both CXCR-4 (upper panel) and SDF-1a (bottom panel) in the
Ad-Ang-1 treated db/db mice, but little co-localization was seen in the Ad-b-gal-treated db/db mice. No specific staining was observed in the sham
control group.
doi:10.1371/journal.pone.0035905.g003
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TUNEL-stained heart sections from sham control db/db mouse, db/db mouse treated with Ad-b-gal or Ad-Ang-1 at 24 hours and 14 days of MI.
Myocardial and endothelial apoptotic cells in the infarcted area of the ischemic hearts were identified by TUNEL staining (green) and TUNEL/vWF
(red) positive staining, and total nuclei by DAPI counterstaining (blue). B and C. Quantitative analysis of apoptotic cells in sham control db/db mouse
and infarcted area of db/db mouse treated with Ad-b-gal or Ad-Ang-1 at 24 hours and 14 days after ischemia. TUNEL or TUNEL/vWF positive cells are
expressed as the total number of per mm
2. Apoptotic cells were significantly decreased in Ad-Ang-1 compared to Ad-b-gal mice. All data represent
mean 6 SD (n=4 mice); *p,0.05. D. Representative images and quantitative analysis of apoptotic cells in the remote area of infarction of db/db
mouse at 24 hours after ischemia. Apoptotic cells were significantly decreased in Ad-Ang-1 treated db/db mouse hearts (n=5) compared to Ad-b-gal
treated db/db mice (n=7). All data represent mean 6 SD; sham control n=5, *p,0.05. E. Representative images of TUNEL and SMA-stained heart
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+ was
significantly increased in db/db mice treated with Ad-Ang-1
compared to db/db mice treated with Ad-b-gal (Figure 5A and
B). Overexpression of Ang-1 in BM also resulted in a significant
increase in VEGF expression (Figure 5C). Further, overexpres-
sion of Ang-1 in db/db mouse hearts resulted in a significant
increase in myocardial capillary density at 14 days in the border
zone of infarcted myocardium compared to db/db mice treated
with Ad-b-gal (Figure 5D and E). The sham control had little
effect on BM-CD31
+ cells and myocardial capillary density (data
not shown).
Overexpression of Ang-1 increases BM-SMA
+ cells and
number of VSMC in the db/db mouse hearts
The number of BM-SMA
+ cells was significantly increased in
db/db mice treated with Ad-Ang-1 compared to db/db mice
treated with Ad-b-gal after MI (Figure 6A & B). Next, the
number of VSMC in the ischemic area was examined after
24 hours of ischemia by the co-localization of Ang-1 with SMA.
Ang-1 expression co-localized with SMA (middle panel). After
2 weeks of MI, Ang-1-positive arteriole with large diameter was
also found in the border zone of infarcted myocardial area
(Figure 6C). Sham control had little effect on BM-SMA
+ and
VSMC cell number (Data not shown).
sections from sham control db/db mouse, db/db mouse treated with Ad-b-gal or Ad-Ang-1 at 24 hours and 14 days of MI. Myocardial and SMCs
apoptotic cells in the infarcted area of the ischemic hearts were identified by TUNEL (green) and SMA (red) positive staining, and total nuclei by DAPI
counterstaining (blue). F. Representative images of cardiac fibrosis formation and quantitative analysis of cardiac fibrosis area in db/db mice treated
with Ad-b-gal or Ad-Ang-1 stained by Masson’s trichrome. Ad-Ang-1 significantly attenuated area of cardiac fibrosis in db/db mice compared to Ad-b-
gal mice. All data represent mean 6 SD (n=5 mice); *p,0.05. G. Heart weight/body weight (HW/BW) ratio in db/db and Ad-Ang-1-treated db/db
mouse hearts at 14 days after MI. Treatment with Ad-Ang-1 significantly attenuated cardiac hypertrophy in db/db mouse hearts (n=5) compared to
Ad-b-gal mice (n=4). All data represent mean 6 SD; *p,0.05.
doi:10.1371/journal.pone.0035905.g004
Figure 5. Ang-1 increases CD31
+ cells and VEGF expression in the BM and promotes capillary formation in db/db mouse hearts. A.
Representative images showing that BM cells differentiate into CD31
+ cells in Ad-b-gal treated db/db mice subjected to myocardial ischemia for
24 hours (left panel) and in the Ad-Ang-1treated db/db mice (right panel). B. Quantitative analysis of BM differentiation into CD31
+ after myocardial
ischemia. The number of BM cells that differentiate into CD31
+ was significantly increased in the Ad-Ang-1treated db/db mice compared to the Ad-b-
gal treated db/db mice. There was not difference between sham control and ischemic group. All data represent mean 6 SD (n=3 mice); *p,0.05. C.
Western blot densitometric analysis of VEGF expression revealed that systemic delivery of Ad-Ang-1 resulted in a significant increase in VEGF
expression in the BM of db/db mouse compared to the Ad-b-gal db/db treated mice. All data represent mean 6 SD (n=3 mice); *p,0.05. D and E.
Representative images and quantitative analysis showing that treatment with Ad-Ang-1 significantly increased capillary formation in db/db mice
subjected to ischemia compared to Ad-a ˆ-gal-treated db/db mice. All data represent mean 6 SD (n=7 mice); *p,0.05.
doi:10.1371/journal.pone.0035905.g005
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and apelin expression in diabetic db/db mouse hearts
To explore the potential intracellular molecular mechanisms by
which overexpression of Ang-1 increased angiogenesis in diabetes,
myocardial Jagged 1/Notch3 and apelin/APLNR expression in
db/db mice was examined. Systemic delivery of Ad-Ang-1 resulted
in a significant increase in Jagged 1 and Notch3 expression
24 hours after myocardial ischemia compared to Ad-b-gal
(Figure 7A and B). Immunohistochemical analysis confirmed
that the increased Notch3 localized in the wall of vessels in diabetic
infarcted hearts treated with Ad-Ang-1 (Figure 7C). Systemic
delivery of Ad-Ang-1 also leads to a significant increase in apelin
expression at 24 hours after MI compared to Ad-b-gal
(Figure 7D). APLNR (APJ) expression in the db/db mice treated
with Ad-Ang-1 showed a trend to increase, however, failed to
achieve statistical significance (Figure 7E). Sham control had
little effect on Jagged1/Notch3 and apelin/APLNR expression
(Data not shown).
Overexpession of Ang-1 improves diabetic cardiac
function after myocardial ischemia
To determine whether increased homing of hematopoietic stem
cell and angiogenesis by Ang-1 promoted cardiac functional
recovery, cardiac function was measured by P-V loop at 14 days of
myocardial ischemia. As shown in Fig 8 A and B, exposure of
diabetic hearts to ischemia for 14 days resulted in a dramatic
reduction of cardiac output (CO) and ejection fraction (EF%).
Overexpression of Ang-1 led to a significant improvement of CO
and EF% in diabetic infarcted hearts.
Discussion
Our data establish, for the first time, that Ang-1 plays a critical
role in the recruitment of hematopoietic stem cell CD133
+/c-kit
+
and CD45
+ cells into ischemic areas of the diabetic infarcted heart.
This is accompanied with a significant reduction in myocardial/
endothelial apoptosis and cardiac hypertrophy as well as fibrosis
formation in diabetic heart. Our study also demonstrates that
Figure 6. Ang-1 increases number of SMA
+ cells in the db/db mouse BM and hearts. A. Representative images showing that BM cells
differentiate into vascular smooth muscle-like (SMA
+) cells in Ad-b-gal treated db/db mice subjected to MI for 24 hours (left panel) and in the Ad-Ang-
1treated db/db mice (right panel). B. Quantitative analysis showing a significant increase in number of SMA
+ cells after myocardial ischemia for
24 hours following Ad-Ang-1 compared to Ad-b-gal in db/db mice subjected to MI. All data represent mean 6 SD (n=3 mice); *p,0.05. C.
Representative images of myocardial VSMC in infarcted areas in db/db+IS+Ad-b-gal and db/db+IS+Ad-Ang-l mice stained by Ang-1
+/SMA
+ cells. Ang-
1 was stained with monoclonal anti-angiopoietin-1 linked to FITC (green, 40X). VSMCs were stained with smooth muscle actin (SMA, Red, 40X) and
nuclei were stained with DAPI counterstaining (blue, 40x). Merged image showed that over-expressed Ang-1 co-localized with VSMC. Top and middle
panel: representative images showing that systemic delivery of Ad-Ang-1 led to a dramatic increase in the number of Ang-1
+/SMA
+ cells in db/db
mouse subjected to myocardial ischemia for 24 hours compared to Ad-b-gal in db/db mice. Bottom panel: representative images showing the newly
formed arteriole (Ang-1
+/ SMA
+) in the Ad-Ang-1 treated db/db mouse heart after ischemia for 14 days.
doi:10.1371/journal.pone.0035905.g006
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infarcted hearts is a novel downstream signaling pathway of Ang-
1-mediated recruitment of CD133
+ cells. Further, our studies
reveal that overexpression of Ang-1 results in increases in capillary
density and arteriole formation together with a dramatic improve-
ment of cardiac functional recovery in the diabetic infarcted
hearts. These studies strongly suggest that Ang-1 gene therapy
protects the diabetic heart from ischemic injury by promoting
Figure 7. Ang-1 upregulates Jagged1, Notch3 and apelin expression in db/db mouse hearts. A. Western blot densitometry analysis of
myocardial Jagged 1 expression showing that systemic delivery of Ad-Ang-1 resulted in a significant increase in Jagged 1 expression in the db/db
mice subjected to myocardial ischemia for 24 hours compare to the db/db mice treated with Ad-b-gal. All data represent mean 6 SD (n=4 mice);
*p,0.05. B. Western blot densitometric analysis of myocardial Notch3 expression revealing that systemic delivery of Ad-Ang-1 (n=5) resulted in
a significant increase in Notch3 expression in db/db mice subjected to myocardial ischemia for 24 hours compare to the db/db mice treated with Ad-
b-gal (n=4). All data represent mean 6 SD; *p,0.05. C. Immunofluorescence microscopy showing expression of Notch3 in the vascular wall of db/db
mice infarcted hearts treated with Ad-Ang-1. Merged images showed that Notch3 expression was expressed in newly formed arteriole of the Ad-Ang-
1 treated db/db mice (right panel), but not the Ad-b-gal-treated db/db mice (left panel). Notch3 was stained with Notch antibody conjugated to FITC
(green, 40X) and nuclei were stained by DAPI (blue). No specific staining was observed in the sham control group. D. Western blot densitometry
analysis showing that apelin expression was significantly increased in the db/db mice treated with Ad-Ang-1 compare to the Ad-b-gal treated db/db
mice at 24 hours of ischemia. All data represent mean 6 SD (n=4 mice); *p,0.05. E. APLNR expression was increased in the Ad-Ang-1 treated db/db
mice compare to the Ad-b-gal treated db/db mice at 24 hours of ischemia, but did not achieve a statistical significantly difference. All data represent
mean 6 SD (n=4 mice); p.0.05.
doi:10.1371/journal.pone.0035905.g007
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+ and c-kit
+ stem cell recruitment, and enhancing
angiogenesis via a mechanism involving SDF-1a/CXCR-4
signaling.
Increasing evidence reveals that Ang-1 has a burgeoning role in
heart disease and possesses cardioprotective effects against
myocardial ischemia [18]
,[19]. Previously, we showed that over-
expression of Ang-1 increases myocardial angiogenesis and
decreases myocardial infarction in STZ mouse model, indicating
a potential link between angiogenesis and reduction of MI in
diabetes [12]. The present studies further reveal that over-
expression of Ang-1 in db/db mouse hearts results in a significant
reduction in myocardial apoptosis as well as endothelial cell
apoptosis. This was accompanied by significant increase in
capillary density and cardiac functional recovery. Although
overexpression of Ang-1 alleviates myocardial ischemic injury in
the STZ and db/db diabetic animal models, [4,12] the underlying
mechanisms by which overexpression of Ang-1 attenuates
myocardial apoptosis and promotes cardiac repair are not
completely understood.
Previous studies showed that Tie-2 expression was detected in
hematopoietic stem cell and Tie-2 signaling was crucial for the
maintenance of the hematopoietic microenvironment. Ang-1
actives Tie-2 on hematopoietic stem cell in the niche, maintains
the in vivo repopulation ability of hematopoietic stem cell.[13]
Recent evidence suggests that hematopoietic stem cell CD133
+
cells are involved in healing the ischemic myocardium and thus
may be important in functional recovery of the myocardium
following acute infarction (AMI) [20–22]. In non-diabetic patients
with AMI, there is often a surge of CD133
+ cells in the circulation.
However, in diabetic patients experiencing AMI, CD133
+ cell
recruitment and function was significantly impaired [20]. CD133
+
cells have been reported to release large amounts of VEGF, which
activates PI3K/Akt and exerts pro-angiogenic and pro-survival
effects. Transplantation of a low number of CD133
+ human fetal
aorta-derived vascular progenitor cells promotes reparative
neovascularization and skeletal myocyte regeneration in a non-
diabetic ischemic hind-limb model [22]. Intriguingly, local therapy
with CD133
+ cells promotes angiogenesis and significantly
accelerates healing of ischemic hind-limb skin wounds in a diabetes
mellitus model [21]. To our knowledge, the present study is the
first demonstration showing that overexpression of Ang-1
significantly increases the recruitment of CD133
+ and c-kit
+ into
myocardial ischemic areas in diabetic db/db mice. Previously, we
have shown that overexpression of Ang-1 significantly increases
myocardial VEGF, Akt and eNOS expression in db/db mice [4].
Based upon these findings, we postulate that Ang-1 promotes
CD133
+ cell and c-kit
+ recruitment into ischemic areas, leading to
secretion of VEGF and activation of the Akt/eNOS signaling
pathway, which exert beneficial effects on the diabetic infarcted
hearts. This notion is supported by our findings that CXCR-4 and
SDF-1a, the chemokine for hematopoietic progenitor cells, were
significantly increased within the ischemic myocardium of Ang-1
treated db/db mouse. Furthermore, our data reveal that the
increased CD133
+ co-localize with CXCR-4
+ and SDF-1a
+ cells
in the area of myocardial ischemia. In addition, SDF-1a/CXCR-4
has been shown to protect the hearts after myocardial infarction
[14,23,24]. These findings suggest that activation of SDF-1a/
CXCR-4 signaling mediates Ang-1-induced recruitment of
CD133
+ progenitor cells into the infarcted ischemic heart leading
to attenuation of myocardial apoptosis. In addition, our present
study shows that Ang-1 protects myocardial endothelial cell
against ischemia-induced endothelial apoptosis. Our previous
study showed that Ang-1 increases myocardial angiogenesis via
activation of Tie-2/Akt/eNOS pathway in coronary endothelial
cells [25]. These direct protective effects of Ang-1 on endothelial
cells may also contribute to the attenuation of myocardial ischemic
injury and increase in myocardial angiogenesis and cardiac
function in diabetes.
Ang-1/Tie-2 signaling plays a predominant role in controlling
both VSMC and pericyte maturation and is essential for the
maintenance of vascular stabilization [1,26]. We have demon-
strated that overexpression of Ang-1 increases VSMC recruitment
and promotes mature neovessel formation; this is accompanied by
a significant increase in capillary density in db/db mouse hearts
[4]. However, the intracellular molecular mechanisms by which
Ang-1 increases VSMC recruitment and maturation remains
unexplored. The Notch ligand Jagged1 is essential for vascular
remodeling and has been linked to congenital heart failure in
humans [27]. Jagged1 plays a critical role in the regulation of
VSMC recruitment/maturation via Notch3 during early embry-
onic development [28]. Deficiency of Notch3 has been shown to
disrupt VSMC differentiation and to increase infarct size in
ischemic stroke [29–31]. Recent studies reveal that ethanol and
cyclic strain stimulate endothelial cell angiogenic activity via
a Notch/Ang-1/Tie-2 pathway suggesting potential cross-talk
between Notch signaling and the Ang-1/Tie-2 pathway [32,33].
The present data show that overexpression of Ang-1 significantly
increased Jagged 1 and Notch3 expression in the db/db mouse
Figure 8. Overexpression of Ang-1 improves cardiac functional recovery of post-MI in db/db mice. A. Cardiac output (CO) was
significantly improved in the db/db mice treated with Ad-Ang-1 (n=5) compare to the Ad-b-gal treated db/db mice (n=4) at 14 days of ischemia.
Sham control (n=4). All data represent mean 6 SD; *p,0.05. B. Myocardial ejection fraction (EF%) was significantly increased in the db/db mice
treated with Ad-Ang-1 (n=5) compare to the Ad-b-gal treated db/db mice (n=4) at 14 days of ischemia. Sham control (n=4). All data represent
mean 6 SD; *p,0.05.
doi:10.1371/journal.pone.0035905.g008
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Notch3 expression was localized to the wall of larger arterioles.
Apelin is an endogenous ligand of the human orphan G-protein-
coupled receptor APJ [34,35]. Apelin exerts a variety of
cardiovascular effects and particularly acts as an activator of
angiogenesis [36–39]. A recent study also reported that the apelin/
APJ system was involved in the regulation of blood vessel diameter
during angiogenesis [40]. Our present data also demonstrated that
treatment with Ad-Ang-1 significantly increase apelin expression.
These data suggest potential role of Jagged1/Notch3 and apelin in
Ang-1-mediated angiogenesis. Most intriguingly, overexpression of
Ang-1 increases the number of BM-SMA
+ cells as well as Ang-1
+/
SMA
+ cells in the diabetic infarcted hearts, suggesting that Ang-1
over-expressing SMA
+ cells in the BM may also be recruited to the
ischemic myocardium rather than their homing to Ang-1
+ cells in
the heart itself.
Recruited CD45
+ cells represent a rich source of hematopoietic
stem cell cytokines in the ischemic heart.[41] Our data showed
that CD45
+ cells were dramatically increased in diabetic infarcted
hearts after Ad-Ang-1 treatment. Furthermore, the abundance
Tie-2-expressing CD45
+ cell was increased implying that these
cells may contribute to the Ang-1-mediated angiogenic response in
diabetic infarcted hearts. Our data also demonstrate that over-
expression of Ang-1 significantly increased BM-derived CD31
+
cells and upregulated VEGF expression in BM. Recent studies
showed that BM-CD31
+ cells were enriched with remarkably
higher levels of angiogenic and hematopoietic genes as compared
to BM-CD31
2 cells. Furthermore, BM-CD31
+ cells induced the
activation of angiogenic, anti-apoptotic and chemo-attractant
factors in ischemic hind-limbs via a paracrine effect. Trans-
plantation with BM-CD31
+ cells significantly increased angiogen-
esis and improved recovery from ischemia [42,43]. Jagged1 has
been shown to drive immature BM progenitor cells to differentiate
into functional EPCs [44]. Jagged1 and Notch3 were increased
during the differentiation of BM-derived mononuclear cells into
VSMC and EC [45]. Further studies are needed to elucidate the
molecular mechanisms and crosstalk between the Jagged1/Notch3
and Ang-1/Tie-2 pathways in the regulation of BM/stem cell
recruitment/differentiation into VSMC/EC and vascular matu-
ration.
The present study demonstrates that following myocardial
ischemia, Ang-1 gene therapy promotes hematopoietic stem cell
recruitment. These changes are associated with an increase in
CXCR-4/SDF-1a expression and myocardial angiogenesis and
with a reduction in cardiac hypertrophy and improvement of
cardiac functional recovery after ischemia. Given the roles of Ang-
1/Tie-2 signaling in hematopoietic stem cell development as well
as EC/VSMCs differentiation, our data provide novel insights into
the intracellular pathways that regulate the formation of mature
vasculature in the diabetic infarcted heart and mechanisms that
promote cardiac repair. Our studies may aid in the development
of novel therapeutic avenues to ameliorate the impaired stem cell
function and insufficient angiogenesis that are characteristic of the
diabetic state.
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